Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?

S. Jauhar; S. Guloksuz; O. Andlauer; G. Lydall; J.G. Marques; L. Mendonca; I. Dumitrescu; C. Roventa; N. De Vriendt; J.S. van Zanten; F. Riese; I. Nwachukwu; A. Nawka; R. Psaras; N. Masson; R. Krishnadas; U. Volpe

doi:10.1186/1471-244X-12-27

Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?

S. Jauhar, S. Guloksuz, O. Andlauer, G. Lydall, J.G. Marques, L. Mendonca, I. Dumitrescu, C. Roventa, N. De Vriendt, J.S. van Zanten, F. Riese, I. Nwachukwu, A. Nawka, R. Psaras, N. Masson, R. Krishnadas, U. Volpe

Research output: Contribution to Journal › Article › Academic › peer-review

178 Downloads (Pure)

Abstract

Background: Little is known about the factors influencing treatment choice in psychosis, the majority of this work being conducted with specialists (consultant) in psychiatry. We sought to examine trainees' choices of treatment for psychosis if they had to prescribe it for themselves, their patients, and factors influencing decision-making.Methods: Cross-sectional, semi-structured questionnaire-based study.Results: Of the 726 respondents (response rate = 66%), the majority chose second-generation antipsychotics (SGAs) if they had to prescribe it for themselves (n = 530, 93%) or for their patients (n = 546, 94%). The main factor influencing choice was perceived efficacy, 84.8% (n = 475) of trainees stating this was the most important factor for the patient, and 77.8% (n = 404) stating this was the most important factor for their own treatment. Trainees with knowledge of trials questioning use of SGAs (CATIE, CUtLASS, TEOSS) were more likely to choose second-generation antipsychotics than those without knowledge of these trials (χ

Original language	English
Article number	27
Pages (from-to)	27
Journal	BMC Psychiatry
Volume	12
DOIs	https://doi.org/10.1186/1471-244X-12-27
Publication status	Published - 2012

Access to Document

10.1186/1471-244X-12-27

301750Final published version, 260 KB

Cite this

Jauhar, S., Guloksuz, S., Andlauer, O., Lydall, G., Marques, J. G., Mendonca, L., Dumitrescu, I., Roventa, C., De Vriendt, N., van Zanten, J. S., Riese, F., Nwachukwu, I., Nawka, A., Psaras, R., Masson, N., Krishnadas, R., & Volpe, U. (2012). Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry, 12, 27. [27]. https://doi.org/10.1186/1471-244X-12-27

Jauhar, S. ; Guloksuz, S. ; Andlauer, O. ; Lydall, G. ; Marques, J.G. ; Mendonca, L. ; Dumitrescu, I. ; Roventa, C. ; De Vriendt, N. ; van Zanten, J.S. ; Riese, F. ; Nwachukwu, I. ; Nawka, A. ; Psaras, R. ; Masson, N. ; Krishnadas, R. ; Volpe, U. / Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?. In: BMC Psychiatry. 2012 ; Vol. 12. pp. 27.

@article{bf9bfd50e16c4fca8a19d24a6b45dda3,

title = "Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?",

abstract = "Background: Little is known about the factors influencing treatment choice in psychosis, the majority of this work being conducted with specialists (consultant) in psychiatry. We sought to examine trainees' choices of treatment for psychosis if they had to prescribe it for themselves, their patients, and factors influencing decision-making.Methods: Cross-sectional, semi-structured questionnaire-based study.Results: Of the 726 respondents (response rate = 66%), the majority chose second-generation antipsychotics (SGAs) if they had to prescribe it for themselves (n = 530, 93%) or for their patients (n = 546, 94%). The main factor influencing choice was perceived efficacy, 84.8% (n = 475) of trainees stating this was the most important factor for the patient, and 77.8% (n = 404) stating this was the most important factor for their own treatment. Trainees with knowledge of trials questioning use of SGAs (CATIE, CUtLASS, TEOSS) were more likely to choose second-generation antipsychotics than those without knowledge of these trials (χ",

author = "S. Jauhar and S. Guloksuz and O. Andlauer and G. Lydall and J.G. Marques and L. Mendonca and I. Dumitrescu and C. Roventa and {De Vriendt}, N. and {van Zanten}, J.S. and F. Riese and I. Nwachukwu and A. Nawka and R. Psaras and N. Masson and R. Krishnadas and U. Volpe",

year = "2012",

doi = "10.1186/1471-244X-12-27",

language = "English",

volume = "12",

pages = "27",

journal = "BMC Psychiatry",

issn = "1471-244X",

publisher = "BioMed Central",

}

Jauhar, S, Guloksuz, S, Andlauer, O, Lydall, G, Marques, JG, Mendonca, L, Dumitrescu, I, Roventa, C, De Vriendt, N, van Zanten, JS, Riese, F, Nwachukwu, I, Nawka, A, Psaras, R, Masson, N, Krishnadas, R & Volpe, U 2012, 'Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?', BMC Psychiatry, vol. 12, 27, pp. 27. https://doi.org/10.1186/1471-244X-12-27